Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03689244) enrolled 128 participants in total — 64 received a placebo (an inactive treatment) and 64 received a medicine called selexipag. The trial was studying a condition involving the blood vessels in the lungs, and the main thing it was measuring was a value called **pulmonary vascular resistance (PVR)** — essentially, how much resistance there is to blood flowing through the lung's blood vessels. This main measurement was taken at 20 weeks, comparing each participant's reading at that point to their reading at the start of the trial. A smaller number of participants went on to an open-label phase (where everyone received selexipag), but no outcome data from that phase appears in the reported results. The reported data shows the main outcome as a percentage ratio — that is, what the Week 20 reading was compared to the starting reading, expressed as a percentage. A figure of 100% would mean no change; a figure below 100% would mean the reading went down from the start. For the placebo group, the reported figure was **89.52%**, and for the selexipag group it was **85.15%**. In plain terms, both groups showed a lower PVR reading at Week 20 compared to the start of the trial, with the selexipag group's figure being somewhat lower than the placebo group's figure. No secondary outcome measure data was included in the submitted results, so those figures were not reported. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39326918) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Pulmonary Hypertension Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to sign and date a consent form agreeing to take part
- You are between 18 and 85 years old (or the legal age of consent in your country) at the time of your first screening visit
- You have been diagnosed with a type of high blood pressure in the lungs called CTEPH, which either cannot be treated with surgery, or has continued or come back after surgical or non-surgical procedures to treat it — confirmed by a review committee
- You have pulmonary hypertension (high blood pressure in the lungs) classified in any severity level (Class I through IV) according to the World Health Organization scale
- You are able to walk between 100 metres and 450 metres in a 6-minute walking test at your screening visit
- If you are a woman who could become pregnant, you must have a negative pregnancy test at the start and before treatment begins, agree to monthly pregnancy tests, and use a reliable form of birth control from screening until at least 30 days after finishing the study treatment (if you choose a hormonal contraceptive, you must have been using it for at least one month before joining)
Who may not be able to join:
- You are currently taking part in, or have taken, another experimental treatment within the 3 months before joining this trial
- You have a condition such as drug or alcohol dependency or a psychiatric illness that may affect your ability to follow the study rules or affect the results
- You have another serious, life-threatening illness where doctors expect you to live less than 12 months
- You have a non-surgical lung procedure (balloon pulmonary angioplasty) planned within 26 weeks of joining the trial
- Your pulmonary hypertension medication has been changed or a new one started within 90 days before certain key assessments or before joining (confirm with trial site)
- You have taken certain medications for pulmonary hypertension (including epoprostenol, treprostinil, iloprost, beraprost, or selexipag) within 90 days before joining the trial (except when used during a specific heart test)
- Your water tablets (diuretics) or calcium channel blocker medications have been changed or newly started within one week before a key heart assessment
- You have any other health condition that would prevent you from doing the 6-minute walk test reliably, including needing a walking aid such as a cane or walker
- You have any condition listed as a reason not to take the study drug based on its official prescribing information (confirm with trial site)
- You have any of the following heart or blood vessel conditions: severe coronary heart disease or unstable chest pain; a heart attack within the last 6 months; a serious heart failure that is not being closely monitored; severe heart rhythm problems; a stroke or mini-stroke within the last 3 months; significant heart valve problems unrelated to pulmonary hypertension; or a suspected or confirmed condition where the veins in the lungs are blocked (pulmonary veno-occlusive disease)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Julian Borissoff, MD, PhD, Actelion
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.